Journal of Clinical Pathways spoke with Mohamed Sorror, MD, MSc, Fred Hutchinson Cancer Research Center, regarding the results and larger implications of a study examining survival differences among older patients with AML receiving allogeneic HCT vs non-HCT therapies.
